Literature DB >> 31612062

Association between interleukin-2, interleukin-10, secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions.

Jing-Wei Meng1, Jing-Hui Song2.   

Abstract

The present study was designed to investigate the association between a change in vaginal local immunity and human papilloma virus (HPV) infection outcome in patients with cervical lesions, through the study of the expression of vaginal local immune factors, interleukin (IL)-2, IL-10, secretory immunoglobulin A (sIgA) and IgG, in patients with different grades of cervical lesions and different degrees of cervical lesions caused by HPV infection prior to and following treatment. The experimental group comprised 136 patients with low-grade squamous intraepithelial lesions, 236 patients with high-grade squamous intraepithelial lesions and 133 patients with cervical squamous cell carcinoma, while the control group comprised 100 time- and location-matched healthy women. The concentrations of sIgA, IgG, IL-2 and IL-10 in the vaginal lavage fluid, were detected using ELISA prior to treatment and at 3, 6 and 12 months after treatment. Prior to treatment, differences in HPV infection rate and changes in vaginal immune factors between patients with all grades of lesions and controls were statistically significant (P<0.05). Furthermore, IL-2 and IL-10 expression levels and the IL-2/IL-10 ratio in patients with different grades of lesions, with or without seroconversion, were significantly different to those in controls (P<0.05). However, the differences between changes in IgG and sIgA expression between patients with HPV seroconversion and patients with persistent HPV infection were not statistically significant (P>0.05). The results of the present study suggest that the restoration of humoral immune function promotes HPV seroconversion, and that IL-2 and IL-10 levels and their ratio may reflect the severity of cervical lesions and treatment effects to a certain extent.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  cervical intraepithelial neoplasia; human papilloma virus; vaginal local immune factors

Year:  2019        PMID: 31612062      PMCID: PMC6781750          DOI: 10.3892/ol.2019.10897

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  21 in total

1.  Immunoglobulins and secretory component in endometrium and cervix. Influence of inflammation and carcinoma.

Authors:  J Hurlimann; R Dayal; E Gloor
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1978-03-10

2.  Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.

Authors:  T D de Gruijl; H J Bontkes; J M Walboomers; J T Schiller; M J Stukart; B S Groot; M M Chabaud; A J Remmink; R H Verheijen; T J Helmerhorst; C J Meijer; R J Scheper
Journal:  J Natl Cancer Inst       Date:  1997-05-07       Impact factor: 13.506

3.  Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies.

Authors:  A A J M van de Ven; W J M Janssen; L S Schulz; A M van Loon; K Voorkamp; E A M Sanders; J G Kusters; S Nierkens; M Boes; A M J Wensing; J M van Montfrans
Journal:  J Clin Immunol       Date:  2014-08-19       Impact factor: 8.317

4.  Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection.

Authors:  Akiko Kobayashi; Ruth M Greenblatt; Kathryn Anastos; Howard Minkoff; Leslie S Massad; Mary Young; Alexandra M Levine; Teresa M Darragh; Vivian Weinberg; Karen K Smith-McCune
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

5.  Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.

Authors:  Catherine B Pineo; Inga I Hitzeroth; Edward P Rybicki
Journal:  Plant Biotechnol J       Date:  2013-08-07       Impact factor: 9.803

6.  Cervical cancer screening in immunocompromised women.

Authors:  Minh Ly Nguyen; Lisa Flowers
Journal:  Obstet Gynecol Clin North Am       Date:  2013-05-10       Impact factor: 2.844

7.  Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia.

Authors:  Jo-Ann S Passmore; Dianne J Marais; Candice Sampson; Bruce Allan; Neelofar Parker; Michelle Milner; Lynnette Denny; Anna-Lise Williamson
Journal:  J Med Virol       Date:  2007-09       Impact factor: 2.327

8.  Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up.

Authors:  K E Jensen; S Schmiedel; B Norrild; K Frederiksen; T Iftner; S K Kjaer
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

9.  Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells.

Authors:  Kenshiro Tsuda; Keiichi Yamanaka; Hiroshi Kitagawa; Tomoko Akeda; Masanao Naka; Kaori Niwa; Takehisa Nakanishi; Masato Kakeda; Esteban C Gabazza; Hitoshi Mizutani
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

10.  IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes.

Authors:  Adriana C Vidal; David Skaar; Rachel Maguire; Seyram Dodor; Laura W Musselwhite; John A Bartlett; Olola Oneko; Joseph Obure; Pendo Mlay; Susan K Murphy; Cathrine Hoyo
Journal:  Infect Agent Cancer       Date:  2015-03-20       Impact factor: 2.965

View more
  2 in total

Review 1.  Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, "I Am like a Box of Complexity, You Never Know What You Are Gonna Get".

Authors:  Ehsan Soleymaninejadian; Paola Zelini; Irene Cassaniti; Fausto Baldanti; Mattia Dominoni; Andrea Gritti; Barbara Gardella
Journal:  Vaccines (Basel)       Date:  2022-05-06

2.  CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.

Authors:  Hao Xu; Song-Shan Chai; Peng Lv; Jia-Jing Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.